EXPOSURE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: ANALYSIS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL

Byong Duk Ye  ¹     Jaroslaw Leszczyszyn  ²     Robert Dudkowiak  ²     Adi Lahat  ³     Beata Gawdis-Wojnarska  ⁴     Aldis Pukitis  ⁵     Marek Horynski  ⁶     Katalin Farkas  ⁷     Jaroslaw Kierkus  ⁸     Maciej Kowalski  ⁹     Stefan Schreiber  ¹⁰     Walter Reinisch  ¹¹     Sang Joon Lee  ¹²     Sung Hyun Kim  ¹²     Jee Hye Suh  ¹²     Mi Rim Kim  ¹²     Han Na Kim  ¹²     Shomron Ben-Horin  ^12    
1 University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (Republic of)
² Melita Medical, Wroclaw, Poland
³ Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel
⁴ Twoja Przychodnia - Szczeci?skie Centrum Medyczne, Szczecin, Poland
⁵ Pauls Stradins Clinical University Hospital, Riga, Latvia
⁶ Endoskopia Sp. z o.o., Sopot, Poland
⁷ Szent Imre Egyetemi Oktatókórház, Budapest, Hungary
⁸ Instytut Pomnik Centrum Zdrowia Dziecka, Warszawa, Poland
⁹ Centrum Diagnostyczno - Lecznicze Barska Sp. z o.o, Wloclawek, Poland
¹⁰ University Hospital Schleswig-Holstein, Kiel, Germany
¹¹ Medical University of Vienna, Vienna, Austria
¹² Celltrion, Inc., Incheon, Korea (Republic of)

Session
IBD Clinical III

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)